ORIC Pharma drops after early-stage trial data for prostate cancer therapy
Source: SeekingAlpha
2026-04-01 07:46:07 ET
More on ORIC Pharmaceuticals
- ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript
- ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
- ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside
- ORIC Pharmaceuticals GAAP EPS of -$0.30 beats by $0.06
- ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones
Read the full article on Seeking Alpha
For further details see:
ORIC Pharma drops after early-stage trial data for prostate cancer therapy
Oric Pharmaceuticals Inc.
NASDAQ: ORIC
ORIC Trading
-3.15% G/L:
$10.47 Last:
436,885 Volume:
$10.755 Open:
ORIC Latest News
July 20, 2026 08:30:00 am
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
May 04, 2026 04:05:00 pm
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
$1,023,561,322
83,384,701
0.22%
39
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
